Read More

EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody

Ocean Biomedical (NASDAQ: OCEA) announced that its Scientific Co-founder, Jack Elias, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 (CHI3L1) in the growth of triple-negative breast cancer. 

OCEA

Read More

Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment

William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other 

VTGN